Breast Cancer, Gastric/Gastroesophageal Junction Cancer
Conditions
Brief summary
This is an open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard 3 + 3 design was used for dose escalation. There are 3 proposed dose levels which are 10, 15, and 20 mg/kg, but dosing interval may be adjusted during the study (such as QW, OR Q2W, OR Q3W) based on emerging data from this trial and/or from phase 1 trial of KN026 in other country. Dose escalation will continue until the maximum tolerated dose (MTD) is reached or if MTD is not found, dose escalation will continue until the MAD of 20 mg / kg is reached.
Interventions
DRUGKN026
Patient will be intravenously administrated with one dose of KN026 every week or every other week.
Sponsors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female subject \>= 18 years * Histologically/cytologically confirmed, locally advanced unresectable or metastatic breast cancer or gastric cancer. * ECOG score 0 or 1 * Life expectancy \>3 months * According to the definition of RECIST1.1, the patient has at least one measurable lesion * Adequate organ function prior to start treatment with KN026 * Able to understand, voluntarily participate and willing to sign the ICF * Subjects (women of child-bearing potential and males with fertile female partner) must be willing to use viable contraception method.
Exclusion criteria
* Accepted any other anti-tumor drug therapies within 4 weeks before fist dose * Accepted radiotherapy within 4 weeks before enrollment * An anthracyclines antibiotic treatment was received exceeding 300 mg/m² within 90 days before first KN026 dosing, or other equivalent dose antharcyclines * Subjects are eligible with clinically controlled and stable neurologic function \>= 4 weeks, which is no evidence of CNS disease progression; Subjects with spinal cord compression and cancerous meningitis are not eligible * Pregnant or nursing females；or intend pregnancy within this study period or within 6 monthes after the end of this study * History of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation * Severe chronic and active infection, need to system antibiosis/antiviral treatment * Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well controlled, and need locally treatment or repeated drainage
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients experiencing dose limiting toxicities | From screening to up to 28 days |
Secondary
| Measure | Time frame |
|---|---|
| Maximum observed serum concentration (Cmax) of KN026 | Throughout the duration of the study; up to 84 days |
| Time of Maximum observed serum concentration (Tmax) of KN026 | Throughout the duration of the study; up to 84 days |
| Percentage of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest | From screening to up to 196 days |
| The proportion of patients with an objective response (partial response or complete response) as defined by RECIST 1.1 criteria | Throughout the duration of the study; up to 2 years |
| Progression free survival according to RECIST 1.1 criteria | Throughout the duration of the study; up to 2 years |
| Frequency and titer of anti-KN026 antibody | Throughout the duration of the study; up to 2 years |
Countries
United States
Outcome results
None listed